Contact this trialFirst, we need to learn more about you.
Nucleoside Reverse Transcriptase Inhibitor
EDP-514 for Hepatitis B Virus Infections
Recruiting0 awardsPhase 1
Catonsville, Maryland
This trial will assess the safety and efficacy of EDP-514, a new drug for Hepatitis B, in two parts. In the first part, healthy adults will take the drug to assess safety and tolerability. In the second part, patients with chronic Hepatitis B will take the drug to assess its ability to fight the virus.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service